Related Experiment Videos
Successful alpha-interferon therapy in a child with chronic refractory idiopathic thrombocytopenic purpura: a case
1Department of Pediatrics, School of Medicine, Niigata University Hospital, Japan.
We treated a sixteen month old male with chronic refractory idiopathic thrombocytopenic purpura (ITP) in whom alpha-interferon (IFN) therapy was effective. He developed ITP which did not respond to various treatments. Six months after admission, we began to treat him with IFN. The patient's platelet count rapidly responded to the therapy and rose above normal range. Serum levels of platelet associated immunoglobulin G (PA-IgG) showed a tendency to decrease with the administration of IFN. After stopping the IFN therapy for a duration of 3 months, the platelet count remained normal. No serious adverse side effects, except transient fever, were observed. From the experience of this case we propose that IFN is one of the therapeutic options for treatment of refractory ITP not only in adults but also in children.
We treated a sixteen month old male with chronic refractory idiopathic thrombocytopenic purpura (ITP) in whom alpha-interferon (IFN) therapy was effective. He developed ITP which did not respond to various treatments. Six months after admission, we began to treat him with IFN. The patient's platelet count rapidly responded to the therapy and rose above normal range. Serum levels of platelet associated immunoglobulin G (PA-IgG) showed a tendency to decrease with the administration of IFN. After stopping the IFN therapy for a duration of 3 months, the platelet count remained normal. No serious adverse side effects, except transient fever, were observed. From the experience of this case we propose that IFN is one of the therapeutic options for treatment of refractory ITP not only in adults but also in children.